Garland J. Scott
SEC Form 4 insider trading activity
Garland J. Scott has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Oct 5, 2026.
On the most recent filing, Garland J. Scott is listed as Director at Enliven Therapeutics, Inc. Inside the rolling window, Garland J. Scott reported no open-market purchases and 1 open-market sale totaling $607K in ELVN.
Companies traded
Other insiders at ELVN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$607K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Garland J. Scott made?
Garland J. Scott has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.
Which companies does Garland J. Scott trade?
Garland J. Scott has filed SEC Form 4 disclosures for 1 company, including ELVN.
When was Garland J. Scott's most recent SEC Form 4 filing?
Garland J. Scott's most recent SEC Form 4 filing on Tracefour is dated Oct 5, 2026.
What is Garland J. Scott's total buy and sell value in the current window?
Inside the rolling retention window, Garland J. Scott bought $0 and sold $607K based on SEC Form 4 filings.
What was Garland J. Scott's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 13,000 ELVN shares on 2026-10-01, worth $607K, per SEC Form 4 filings.